natgillin/translations-raw huggingface dataset:
1 vial 375 mg/5 ml 
1 viala 375 mg/5 ml
• The potential for interactions between Vistide and anti-HIV protease inhibitors has not been studied. 
• Možni medsebojni učinki med zdravilom Vistide in zaviralci proteaz proti HIV niso raziskani.
For those patients who fully recover from cidofovir associated renal toxicity, the benefits-risk balance of reintroducing cidofovir has not yet been evaluated. 
Za tiste bolnike, ki popolnoma okrevajo po okvari ledvic, ki jo je povzročil cidofovir, razmerje med koristjo in tveganji pri ponovni uvedbi cidofovira še ni raziskano.
In both cases, the overdose occurred during the first induction dose and no additional cidofovir therapy was administered. 
V obeh primerih je do prevelikega odmerjanja prišlo med prvim začetnim odmerkom in nadaljnja terapija s cidofovirom ni bila uporabljena.
Chemical and physical in-use stability has been demonstrated for up to 24 hours at 2 - 8ºC when dilution is performed under controlled and validated aseptic conditions. 
Kemična in fizikalna stabilnost med uporabo sta dokazani za 24 ur pri temperaturi od 2-8°C, če je bila raztopitev izvedena pod kontroliranimi in validiranimi aseptičnimi pogoji.
Your doctor may also instruct you to drink plenty of fluids. 
Zdravnik vam bo morda tudi naročil, da pijte veliko tekočin.
• During treatment with Vistide you should receive regular follow-up eye examinations for possible eye irritation, inflammation or swelling. 
• Med zdravljenjem z zdravilom Vistide morate redno opravljati preglede oči zaradi morebitnega draženja, vnetja ali otekanja oči.
Sodium hydroxide Hydrochloric acid Water for injections 
natrijev hidroksid klorovodikova kislina voda za injekcije
The recommended dose, frequency of use, or rate of infusion must not be exceeded. 
Ne sme se preseči priporočenega odmerka, pogostnosti uporabe in hitrosti infundiranja.
Vistide should be used only when other agents are considered unsuitable. 
Zdravilo Vistide naj bi uporabljali le, če druga zdravila niso primerna.
Vistide is formulated for intravenous infusion only and must not be administered by other methods including intraocular injection or topically. 
Zdravilo Vistide je formulirano samo za intravensko infundiranje in se ne sme uporabljati na noben drugačen način, vključno z intraokularnim injiciranjem ali zunanje.
Nausea, vomiting 
Navzea, bruhanje
The major route of elimination of cidofovir was by renal excretion of unchanged drug by a combination of glomerular filtration and tubular secretion. 
Glavna pot izločanja cidofovira je bilo ledvično izločanje nespremenjenega zdravila s kombinacijo glomerulne filtracije in tubulne sekrecije.
Vistide will not stop you passing HIV infection onto other people so you should continue to take precautions to avoid infecting 
Zdravilo Vistidine ne bo preprečilo prenosa okužbe na druge ljudi, zato morate nadaljevati z ustreznimi previdnostnimi ukrepi, da ne okužite drugih.
If you drive or operate machinery, discuss this with your doctor to get their advice about stopping these activities based upon your disease and your tolerance of the medicine. 
Če vozite ali upravljate s stroji, se posvetujte z zdravnikom o prekinitvi dejavnosti glede na vašo bolezen in vaše prenašanje zdravila.
However, in case of difficulty in obtaining probenecid the local representative of the Marketing Authorisation Holder of Vistide should be contacted for information (see also sections 4.2 and 4.4). 
V primeru težav z dobavo probenecida pa se je mogoče za informacije obrniti na lokalnega predstavnika imetnika dovoljenja za promet z zdravilom Vistide (glejte tudi poglavji 4.2 in 4.4).
What Vistide looks like and contents of the pack 
Izgled zdravila Vistide in vsebina pakiranja
Iritis, uveitis, hypotony of the eye (see section 4.4) 
Iritis, uveitis, hipotonija očesa (glejte poglavje 4.4)
Cases of acute renal failure have been reported after only one or two doses of cidofovir. 
Opisani so primeri akutne odpovedi ledvic po le enem ali dveh odmerkih cidofovirja.
There have been reports of reduced white blood counts, liver toxicity, kidney toxicity and destruction of red blood cells. 
Poročali so o znižanem številu belih krvnih celic, jetrni toksičnosti, ledvični toksičnosti in propadu rdečih krvnih celic.
Blood and lymphatic system disorders Very common 
Bolezni krvi in limfatičnega sistema Zelo pogosti
Maintenance treatment. 
Vzdrževalno zdravljenje.
Proteinuria appears to be an early and sensitive indicator of cidofovir-induced nephrotoxicity. 
Kaže, da je proteinurija zgoden in občutljiv kazalec nefrotoksičnih učinkov cidofovira.
There are no data from the use of cidofovir in pregnant women. 
Podatkov o uporabi cidofovira pri nosečnicah ni.
If you are taking zidovudine, you should discuss with your doctor whether to temporarily stop taking zidovudine or decrease the dose of zidovudine by 50% on days when Vistide and probenecid are given. 
Če jemljete zidovudin, se morate z zdravnikom posvetovati, ali naj začasno prekinete uporabo zidovudina ali pa ob dneh, ko dobite zdravilo Vistide in probenecid, zmanjšate odmerek zidovudina za 50%.
It is recommended to discontinue potentially nephrotoxic agents at least 7 days before starting cidofovir. 
Zdravljenje s potencialno nefrotoksičnimi sredstvi je priporočljivo opustiti vsaj 7 dni pred začetkom zdravljenja s cidofovirom.
Not known 
Neznano
CMV attacks the retina of the eye and may cause loss of vision, and eventually lead to blindness. 
CMV napade očesno mrežnico in lahko povzroči poslabšanje vida in končno tudi s slepoto.
Refrigerated infusion bags should be allowed to warm to room temperature prior to use. 
Ohlajene infuzijske vrečke je treba pustiti, da se pred uporabo ogrejejo na sobno temperaturo.
Peri- and post-natal development studies in which female rats received subcutaneous injections of cidofovir once daily at doses up to 1.0 mg/kg/day from day 7 of gestation through day 21 postpartum (approximately 5 weeks) resulted in no adverse effects on viability, growth, behaviour, sexual maturation or reproductive capacity in the offspring. 
Peri- in postnatalne razvojne študije, v katerih so podganje samice enkrat na dan dobivale subkutane injekcije cidofovira v odmerkih do 1,0 mg/kg/dan, in sicer od 7. dne gestacije do 21. postpartalnega dneva (približno 5 tednov), niso pokazale nobenih neželenih učinkov na sposobnost za življenje mladičev, njihovo rast, vedenje, spolno dozorevanje ali reprodukcijsko zmožnost.
Patients receiving both drugs should be closely monitored for zidovudine induced haematological toxicity. 
Bolnike, ki jemljejo obe zdravili, je treba skrbno opazovati glede hematološke toksičnosti, ki jo povzroča zidovodin.
Adverse reactions possibly or probably related to cidofovir based on clinical trial experience and post-marketing surveillance 
Neželeni učinki, morda ali verjetno povezani s cidofovirjem na podlagi kliničnih preskušanj in pomarketinškega spremljanja
Cidofovir diphosphate inhibits these viral polymerases at concentrations that are 8- to 600-fold lower than those needed to inhibit human cellular DNA polymerases alpha, beta, and gamma. 
Cidofovirdifosfat zavre te virusne polimeraze v koncentracijah, ki so od 8- do 600-krat nižje od koncentracij, potrebnih za zavrtje DNA polimeraz alfa, beta in gama v človeških celicah.
Renal insufficiency [creatinine clearance ≤ 55 ml/min or ≥ 2+ proteinuria (≥ 100 mg/dl)] is a contraindication for the use of Vistide (see sections 4.3 and 4.4). 
Ledvična insuficienca [očistek kreatinina ≤ 55 ml/min ali proteinurija ≥ 2+ (≥ 100 mg/dl)] je kontraindikacija za uporabo zdravila Vistide (glejte poglavji 4.3 in 4.4).
If Vistide contacts the skin, wash membranes and flush thoroughly with water. 
Če pride zdravilo Vistide v stik s kožo, jo je treba umiti in temeljito splakniti z vodo.
The therapy should be prescribed by a physician experienced in the management of HIV infection. 
Zdravljenje mora predpisati zdravnik, ki ima izkušnje z vodenjem okužbe s HIV.
Vistide will not cure CMV retinitis but may improve your condition by delaying progression of the disease. 
Zdravilo Vistide citomegalovirusnega retinitisa ne ozdravi, lahko pa izboljša stanje, ker upočasni napredovanje bolezni.
If you have accidentally been given more Vistide than prescribed for you, tell your doctor immediately. 
Če ste pomotoma prejeli večji odmerek zdravila Vistide, kot vam je bil predpisan, to nemudoma povejte zdravniku.
Allergic reactions, with skin inflammation, itching, hives and, rarely, severe allergic reactions, and serious skin reaction have occurred. 
Prišlo je do alergijskih reakcij z vnetjem kože, srbenjem in koprivnico; redko je prišlo tudi do hudih alergijskih reakcij in hudih kožnih reakcij.
Therefore before giving you probenecid your doctor should consult the current prescribing information regarding the safety of probenecid. 
Preden vam predpiše probenecid, mora vaš zdravnik za dodatne podatke o varnosti preveriti veljavne informacije o varnosti probenecida.
At the 4 cidofovir levels (12.5 to 100 µg/ml) tested, the percentage of damaged metaphases and number of aberrations per cell increased in a concentrationdependent manner. 
Pri 4 raziskanih koncentracijah cidofovira (od 12,5 do 100 µg/ml) sta odstotek okvarjenih metafaz in število aberacij na celico naraščala od koncentracije odvisno.
Women of childbearing potential have to use effective contraception during and after treatment with cidofovir. 
Ženske v rodni dobi morajo uporabljati učinkovito kontracepcijo med zdravljenjem s cidofovirom in po njem.
Renal insufficiency/Haemodialysis 
Insuficienca ledvic/hemodializa
The in vitro sensitivity to cidofovir is shown in the following table: 
Občutljivost za cidofovir in vitro prikazuje naslednja preglednica:
In vitro protein binding 
Vezava na beljakovine in vitro
Patients receiving cidofovir must have their serum creatinine and urine protein levels determined on specimens obtained within 24 hours prior to the administration of each dose of cidofovir. 
Pri bolnikih, ki dobivajo cidofovir, je treba koncentracijo kreatinina v serumu in beljakovin v urinu določiti v vzorcih, dobljenih v 24 urah pred vsakim odmerkom cidofovira.
How to take probenecid with Vistide 
Kako jemati probenecid z zdravilom Vistide
Vistide must be given by a doctor or nurse with appropriate experience in treating people with AIDS. 
Zdravilo Vistide mora dati zdravnik ali medicinska sestra z ustreznimi izkušnjami v zdravljenju bolnikov z AIDS-om.
It is unknown whether cidofovir/metabolites are excreted in human milk. 
Ni znano, ali se cidofovir/presnovki izločajo v materino mleko.
High flux haemodialysis has been shown to reduce the serum levels of cidofovir by approximately 75%. 
Dokazano je, da visokopretočna hemodializa zmanjša koncentracijo cidofovira v serumu za približno 75%.
All clinical trials relevant to clinical efficacy evaluation were performed using probenecid concomitantly with cidofovir. 
V vseh kliničnih preizkušanjih, pomembnih za oceno klinične učinkovitosti, so sočasno s cidofovirom uporabljali probenecid.
In vitro protein binding of cidofovir to plasma or serum protein was 10% or less over the cidofovir concentration range 0.25 to 25 µg/ml. 
Vezava cidofovira na beljakovine v plazmi ali serumu in vitro je bila v koncentracijskem območju od 0,25 do 25 µg/ml cidofovira 10% ali manj.
Treatment with Vistide must not be initiated in patients with creatinine clearance ≤ 55 ml/min, or ≥ 2+ proteinuria (≥ 100 mg/dl), as the optimum induction and maintenance doses for patients with moderate to severe renal impairment are not known. 
Zdravljenja z zdravilom Vistide se ne sme začeti pri bolnikih, ki imajo očistek kreatinina ≤ 55 ml/min ali proteinurijo ≥ 2+ (≥ 100 mg/dl), ker optimalni začetni in vzdrževalni odmerki za bolnike z zmerno do hudo okvaro ledvic niso znani.
If you become pregnant while receiving this medication, you must inform your doctor immediately. 
Če zanosite med uporabo tega zdravila, morate nemudoma obvestiti zdravnika.
See the package leaflet for further information. 
Za nadaljne informacije glejte navodilo za uporabo.
Probenecid tablets are given to lower the risk of kidney damage. 
Tablete probenecida se uporabljajo za zmanjšanje tveganja okvare ledvic.
In patients exhibiting ≥ 2+ proteinuria, intravenous hydration should be performed and the test repeated. 
Pri bolnikih s proteinurijo ≥ 2+ je treba opraviti intravensko hidracijo in preiskavo ponoviti.
Refrigerated solutions should be allowed to warm to room temperature prior to use. 
Ohlajeno raztopino je treba pustiti, da se pred uporabo ogreje na sobno temperaturo.
In patients with normal renal function, 80 to 100% of the intravenous dose was recovered in the urine over 24 hours as unchanged cidofovir. 
Pri bolnikih z normalnim delovanjem ledvic se je v 24 urah od 80 do 100-odstotnega intravenskega odmerka izločilo v urinu kot nespremenjeni cidofovir.
Patients receiving cidofovir should be advised to have regular follow-up ophthalmologic examinations for possible occurrence of uveitis/iritis and ocular hypotony. 
Bolnikom, ki dobivajo cidofovir, je treba svetovati, naj redno opravljajo oftalmološke preglede zaradi morebitnega pojava uveitisa/iritisa in očesne hipotonije.
To reduce the risk of kidney damage, you will receive intravenous fluids (normal saline) before each dose of Vistide and probenecid tablets before and after each dose of Vistide (see section 3 below for more information). 
Da bi zmanjšali tveganje za okvaro ledvic, boste dobili intravensko tekočino (fiziološko raztopino) pred vsakim odmerkom zdravila Vistide in tablete probenecida pred in po vsakem odmerku zdravila Vistide (glejte poglavje 3 spodaj za več informacij).
Should not be administered by intraocular injection. 
Ne sme se uporabljati za intraokularno injiciranje.
The safety of cidofovir has not been evaluated in patients receiving other known potentially nephrotoxic agents (e.g. tenofovir, aminoglycosides, amphotericin B, foscarnet, intravenous pentamidine, adefovir and vancomycin). 
Varnost cidofovira ni ugotovljena pri bolnikih, ki dobivajo druge potencialno nefrotoksične učinkovine (npr. tenofovir, aminoglikozide, amfotericin B, foskarnet, intravenski pentamidin, adefovir in vankomicin).
Probenecid may also cause other side effects including loss of appetite, sore gums, flushing, hair loss, dizziness, reduced red blood cell count and increased frequency of passing water (urinating). 
Probenecid lahko povzroči tudi druge neželene učinke, kot so izguba apetita, boleče dlesni, zardevanje, izpadanje las, omotica, znižano število rdečih krvnih celic in večja pogostost odvajanja vode (uriniranja).
5 ml clear glass vials with a 5 ml nominal fill volume. 
5 ml viale iz prozornega stekla za enkratno uporabo, s 5 ml nominalnega polnilnega volumna.
Hypersensitivity reactions, with dermatitis, pruritus, urticaria and, rarely, anaphylaxis, and Stevens-Johnson syndrome have occurred. 
Pojavile so se preobčutljivostne reakcije z dermatitisom, srbenjem, urtikarijo in, redko, anafilaksijo in Stevens-Johnsonovim sindromom.
Two cases of cidofovir overdose have been reported. 
Opisana sta dva primera prevelikega odmerjanja cidofovira.
Preclinical animal studies demonstrated that nephrotoxicity was the major dose-limiting toxicity of cidofovir. 
Predklinične študije na živalih so pokazale, da so nefrotoksični učinki glavni toksični pojavi, ki omejujejo odmerek cidofovira.
Probenecid is known to increase the exposure of many substances (e.g., paracetamol, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicyclic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine). 
Znano je, da probenecid zveča izpostavljenost številnim zdravilom (npr. paracetamolu, acikloviru, zaviralcem angiotenzinske konvertaze, aminosalicilni kislini, barbituratom, benzodiazepinom, bumetanidu, klofibratu, metotreksatu, famotidinu, furosemidu, nesteroidnim protivnetnim zdravilom, teofilinu in zidovudinu).
The preparation of Vistide diluted solution should be done in a laminar flow biological safety cabinet. 
Raztopino zdravila Vistide je treba pripraviti v biološkem varnostnem sistemu z laminarnim pretokom.
Cidofovir enters cells by fluid-phase endocytosis and is phosphorylated to cidofovir monophosphate and subsequently to cidofovir diphosphate. 
Cidofovir vstopi v celice z endocitozo tekoče faze ter se fosforilira v cidofovirmonofosfat in nato v cidofovirdifosfat.
If you get pain, redness or itching of the eye or changes in your vision, tell your doctor promptly. 
Če dobite bolečino, pordelost ali srbenje oči ali spremembe vida, nemudoma obvestitite svojega zdravnika.
Any pain, redness or itching of the eye or changes in your vision should be promptly reported to your doctor so that your treatment can be reviewed. 
Za vsako bolečino, pordelost ali srbenje oči in za vsako spremembo vida morate takoj povedati zdravniku, da bo lahko pretehtal vaše zdravljenje.
Your doctor might instruct you to take other medicines such as anti-emetics (anti sickness medicines), antihistamines and/or paracetamol to decrease the side effects of probenecid. 
Vaš zdravnik vam lahko naroči, da za ublažitev neželenih učinkov probenecida uporabite še druga zdravila, npr. antiemetike (zdravila proti slabosti), antihistaminike in/ali paracetamol.
SPECIAL STORAGE CONDITIONS Do not store above 30°C. 
POSEBNA NAVODILA ZA SHRANJEVANJE Shranjujte pri temperaturi do 30°C.
Prolonged antiviral effects of cidofovir are related to the half-lives of its metabolites; cidofovir diphosphate persists inside cells with a half-life of 17-65 hours and a cidofovir phosphate-choline adduct has a half-life of 87 hours. 
Podaljšano protivirusno učinkovanje cidofovira je povezano z razpolovnimi časi njegovih presnovkov; cidofovirdifosfat ostane v notranjosti celic z razpolovnim časom od 17 do 65 ur; adukt cidofovirfosfat-holin ima razpolovni čas 87 ur.
In patients who develop allergic or hypersensitivity symptoms to probenecid (e.g., rash, fever, chills and anaphylaxis), prophylactic or therapeutic use of an appropriate antihistamine and/or paracetamol should be considered. 
Pri bolnikih, ki doživijo simptome alergije ali preobčutljivosti za probenecid (npr. izpuščaj, zvišana telesna temperatura, mrzlica in anafilaksija), je treba razmisliti o profilaktični ali terapevtski uporabi antihistaminika in/ali paracetamola.
Dilute before use. 
Pred uporabo raztopite.
Ear and labyrinth disorders Not known 
Ušesne bolezni, vključno z motnjami labirinta Neznano
There are no studies of cidofovir on the fertility of men or women. 
Ni študij o vplivu cidofovira na sposobnost razmnoževanja moških ali žensk.
Excess Vistide and all other materials used in the admixture preparation and administration should be placed in a leak-proof, puncture-proof container for disposal. 
Ostanke zdravila Vistide in vseh drugih materialov, ki se uporabljajo za pripravo in apliciranje mešanice, je treba dati v neprepusten, proti vbodom varen vsebnik za odlaganje.
Personnel preparing the solution should wear surgical gloves, safety glasses and a closed front surgical-type gown with knit cuffs. 
Osebje, ki pripravlja raztopino, mora nositi kirurške rokavice, varnostna očala in spredaj zaprto kirurško haljo s stisnjenimi manšetami.
Concomitant use of probenecid is essential for reducing the pronounced nephrotoxicity of cidofovir to an extent that results in an acceptable benefit/risk balance of cidofovir therapy. 
Sočasna uporaba probenecida je za zmanjševanje izrazite nefrotoksičnosti cidofovira bistvena, saj omogoča sprejemljivo razmerje med koristjo in tveganji za zdravljenje s cidofovirom.
At the end of a one-hour infusion of cidofovir 5 mg/kg administered with concomitant oral probenecid, the mean (± SD) serum concentration of cidofovir was 19.6 (± 7.18) µg/ml. 
Na koncu enourne infuzije 5 mg/kg cidofovira, uporabljene sočasno s peroralnim probenecidom, je bila povprečna (± SD) koncentracija cidofovira v serumu 19,6 (± 7,18) µg/ml.
There is a risk that concomitant treatment of Vistide with products containing tenofovir disoproxil fumarate may give rise to a pharmacodynamic interaction and increase the risk of Fanconi syndrome (see section 4.4). 
Obstaja tveganje, da bi lahko sočasno zdravljenje z zdravilom Vistide in zdravili, ki vsebujejo tenofovirdizoproksil fumarat, povzročilo farmakodinamične interakcije in zvišanje tveganja za Fanconijev sindrom (glejte poglavje 4.4).
Renal insufficiency: 
Jetrna insuficienca:
(See sub-sections “How to take probenecid with Vistide” and “How IV fluids are given before Vistide” below.) 
(Glejte spodnji podpoglavji »Kako jemati probenecid z zdravilom Vistide« in »Kako se dajejo i.v.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist immediately. 
Če katerikoli neželeni učinek postane resen ali če opazite katerikoli neželeni učinek, ki ni omenjen v tem navodilu, nemudoma obvestite svojega zdravnika ali farmacevta.
• headache, weakness/fatigue, chills and allergic reactions. 
• vključujejo glavobol, šibkost/utrujenost, mrzlico in alergijske reakcije.
Possible side effects of taking probenecid 
Možni neželeni učinki jemanja probenecida
Skin and subcutaneous tissue disorders Very common 
Bolezni kože in podkožja Zelo pogosti
• adefovir (for HBV infection) 
• adefovir (za okužbe z virusom HBV)
A probenecid desensitisation program is not recommended for use. 
Postopek desenzibilizacije na probenecid ni priporočljiv.
Cidofovir-selected mutants had a mutation in the DNA polymerase gene and were cross-resistant to ganciclovir, but susceptible to foscarnet. 
S cidofovirom selekcionirani mutanti so imeli mutacijo v genu za DNA polimerazo in so bili navzkrižno odporni proti gancikloviru, a občutljivi za foskarnet.
Vistide is not recommended during pregnancy and in women of childbearing potential not using contraception. 
Zdravila Vistide ne uporabljajte pri nosečnicah in pri ženskah v rodni dobi, ki ne uporabljajo učinkovite kontracepcije.
Although not observed in human studies of Vistide, such changes may occur in humans and cause infertility. 
Tega v študijah zdravila Vistide pri ljudeh sicer niso opazili, vendar se takšne spremembe lahko pojavijo tudi pri človeku in povzročijo neplodnost.
Following in vitro selection of ganciclovir-resistant HCMV isolates, cross-resistance between ganciclovir and cidofovir was seen with ganciclovir-selected mutations in the HCMV DNA polymerase gene but not with mutations in the UL97 gene. 
Po in vitro-selekciji izolatov HCMV, odpornih proti gancikloviru, so ugotovili navzkrižno odpornost med ganciklovirom in cidofovirom pri z ganciklovirom selekcioniranih mutacijah v genu DNA polimeraze HCMV, ne pa pri mutacijah v genu UL97.
Two grams of probenecid should be administered 3 hours prior to the cidofovir dose and one gram administered at 2 and again at 8 hours after completion of the 1 hour cidofovir infusion (for a total of 4 grams). 
Dva grama probenecida je treba dati 3 ure pred odmerkom cidofovira, en gram 2 uri in še en gram 8 ur po koncu enourne infuzije cidofovira (skupaj 4 grame).
There have been reports of leukopenia, hepatic necrosis, nephrotic syndrome, and aplastic anaemia. 
Poročali so o levkopeniji, nekrozi jeter, nefrotskem sindromu in aplastični anemiji.
Male patients should be advised that cidofovir caused reduced testes weight and hypospermia in animals. 
Moškim bolnikom je treba povedati, da je cidofovir pri živalih povzročil zmanjšanje teže mod in hipospermijo.
It is not known whether Vistide is passed on to the baby in human milk. 
Ni znano, ali se zdravilo Vistide iz materinega mleka prenaša na otroka.
• In general, women with HIV should not breast-feed in order to avoid passing HIV to their 
• Na splošno je priporočljivo, da ženske, okužene s HIV, ne dojijo svojih otrok, ker se virus lahko prenese na dojenčka z materinim mlekom.
Vistide is contraindicated in patients with renal insufficiency (see section 4.2). 
Zdravilo Vistide je kontraindicirano pri bolnikih z insuficienco ledvic (glejte poglavje 4.2).